PK of Rivaroxaban in Bariatric Patients - Extension

Prophylaxis of Venous Thromboembolism Clinical Trial

Official title:
Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban in Obesity Patients Before and After Bariatric Surgery - The Extension Study

Status Completed

Clinical Trial Summary

Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8 months after bariatric surgery

Clinical Trial Description

Weight loss after bariatric surgery can putatively alter drug disposition of rivaroxaban. This may be due to an altered intestinal adaptations several months after the surgical procedure. The aim of this clinical trial is to investigate pharmacokinetic and pharmacodynamic parameters after single application of 10 mg rivaroxaban in patients with prior bariatric intervention (Roux-en-y-gastric bypass or sleeve gastrectomy 6-8 months ago). PK/PD parameters will be assessed during 12 hours after application of rivaroxaban. ;

Study Design

Related Conditions & MeSH terms

Prophylaxis of Venous Thromboembolism
Thromboembolism
Venous Thromboembolism

Clinical Trial Details

NCT number	NCT02832947
Study type	Interventional
Source	University Hospital Inselspital, Berne
Contact
Status	Completed
Phase	Phase 1
Start date	February 2016
Completion date	October 2016

View Details